by Keishi Foecke | Nov 6, 2025 | Blog Post
Despite decades of biomedical breakthroughs, 95% of the 7,000 identified rare diseases still lack an approved treatment or cure. While these diseases may be individually rare, they collectively impact 1 in 10 Americans. To address these unmet medical needs requires...
by Keishi Foecke | Oct 22, 2025 | Blog Post
Recent commentary from senior Federal Trade Commission (FTC) and Department of Justice (DOJ) officials signaled a continued commitment to activist antitrust enforcement – compounding the uncertainty for thousands of small and early-state life science companies that...
by Keishi Foecke | Oct 9, 2025 | Blog Post
In a recent study published in Concurrences Law & Economics, Cornerstone Research experts found a significant association between biopharmaceutical mergers and acquisitions (M&A) and the likelihood of new and novel therapies coming to market. After analyzing...
by Keishi Foecke | Sep 30, 2025 | PULSE Partner
In this guest blog, Kristin Jones, CEO of PULSE Partner Indiana Life Sciences Association, discusses how pro-competitive mergers and acquisitions (M&A) have played a crucial role in supporting collaborations between universities, academic researchers and life...
by Keishi Foecke | Sep 4, 2025 | Blog Post
Following a recent Trump Administration executive order, the Federal Trade Commission (FTC) and Department of Justice (DOJ) both released statements signaling a shift to a more balanced approach to mergers and acquisitions (M&A)...
by Keishi Foecke | Aug 28, 2025 | Blog Post
Investment in early-stage life sciences companies is critical to sustain America’s global leadership in discovering and developing new medical breakthroughs for patients, according to a recent General Catalyst blog, “The Future of Life Sciences Investment.”...
